Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 11Breast Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 8Carcinoma, Merkel Cell 8Neoplasms 7Colorectal Neoplasms 7Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Neuroendocrine 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Sarcoma 2Penile Neoplasms 2Pancreatic Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm, Residual 2Mesothelioma, Malignant 2

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Cisplatin 2sacituzumab govitecan 1erdafitinib 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Muscle Invasive Bladder Urothelial Carcinoma × avelumab × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡